Material and method for differentiating pluripotent stem cells into hematopoietic stem cells

Abstract

The invention discloses a material and a method for differentiating pluripotent stem cells into hematopoietic stem cells, in particular to a culture medium and a method for inducing directional differentiation of the pluripotent stem cells into CD34 + CD43 + CD45 + hematopoietic stem cells. By utilizing the materials (such as an additive I, an additive II and an additive III, or a culture medium I, a culture medium II and a culture medium III) and the method, the directional differentiation of the induced pluripotent stem cells can be realized under a normal oxygen condition, and the CD34 + hematopoietic stem cells can be efficiently obtained. The material provided by the invention has the advantages of definite chemical components, low cost, high safety and stable quality; and the methodhas the advantages of short time consumption, high differentiation efficiency and the like, can provide a large number of cell sources for the fields of tissue engineering, drug research and development, cell treatment and the like, and has favorable application prospects and commercial values.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a material and method for differentiation of pluripotent stem cells into hematopoietic stem cells, in particular to a culture medium and method for inducing directional differentiation of pluripotent stem cells into CD34+CD43+CD45+ hematopoietic stem cells. Background technique [0002] In recent years, hematopoietic stem cells (HSC) have been increasingly used clinically to treat hematological malignancies, solid tumors, bone marrow failure diseases, and some congenital diseases. It also shows certain application development prospects in the treatment of diseases and tumors. With the development of alternative sources of stem cell transplantation, including cord blood and homologous donors, and the use of new conditioning therapies, patient outcomes have been greatly enhanced and improved. Hematopoietic stem cells derived from umbilical cord blood have broad application pro...

AI Technical Summary

Problems solved by technology

However, the supply of umbilical cord blood provided only through voluntary blood donation from donors is far from meeting the large clinical needs. Because a single umbilical cord blood is small in size, it is difficult to meet the treatment needs of adult patients, which seriously restricts the clinical use of umbilical cord blood hematopoietic stem cells. application

Coupled with the risk of contamination of HIV, HCV and other pathogens in clinical blood, as well as the impact of unfavorable factors such as transplant failure, graft-versus-host disease (GVHD) and hematopoietic construction delay, more than 50% of patients are permanently disabled or incurable

Therefore, even with hematopoietic stem cell therapy, there is still a serious problem: how to have a sufficient amount of hematopoietic stem cells for transplantation

However, the process of this differentiation method is complex, with many details, too many human errors, poor repeatability, and the induction efficiency cannot be guaranteed. Moreover, the differentiation culture needs to be carried out under low oxygen conditions, and the early differentiated cells die seriously.

Images